Examining barriers and facilitators to testing lipoprotein(a): Understanding at-risk individual and clinician perspectives
This analysis highlights that Lp(a) testing decisions are multifactorial, providing multiple opportunities for intervention and improvement. Strategies to convey how Lp(a) measurement can inform risk assessment and treatment approaches may be foundational to encouraging more widespread testing.
Authors
- Laurence S. Sperling (ORCID: https://orcid.org/0000-0001-9417-6370)
- Katherine Wilemon (ORCID: https://orcid.org/0000-0003-4629-6866)
- Diane MacDougall (ORCID: https://orcid.org/0009-0004-7332-4185)
- Skye Chernichky‐Karcher (ORCID: https://orcid.org/0000-0002-2393-5824)
- Shoshana H. Bardach (ORCID: https://orcid.org/0000-0002-1342-5863)
- Ana-Louise Hawke
Institutions
- Bloomsburg University (US)
- Heart Foundation (US)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1016/j.jacl.2025.12.002
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00